Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2013 Mar 5;22(5):812–820. doi: 10.1158/1055-9965.EPI-12-1386

Figure 2.

Figure 2

Benchmark dose model for Lai et al. (29) on end stage renal disease (ESRD) prevalence as a function of cumulative MuTong dose in Taiwan.